healthi boost accret drive
view despit alreadi posit pre-announce sector
perform-r still abl deliv high-qual ep beat
biggest posit surpris boost ge biopharma
accret thank oper upsid lower
financ cost result impli guidanc
consensu midpoint acquisit track close
high-qual beat initi guidanc expect
includ upsid accret end fiscal year
strong high-qual beat even rais expect
posit pre-announce feel-good includ organ growth
led life scienc diagnost core margin expans
bp strong increment full-year convers
biggest upsid surpris boost ge biopharma
accret estim driven oper upsid
lower financ cost assum deal close quarter-end
would lift cash ep result impli
guidanc rang vs consensu organ revenu
growth target though mind yet
bake headwind wuhan coronaviru outbreak regardless
result well-receiv investor drive stock bp
out-performance vs peer next major catalyst
close deal rais cash
ep estim price target
biggest surpris boost accret
number move piec drive accret boost includ
lower financ cost better oper perform
dilut small life scienc divestitur note
manag expect ge biopharma achiev low-double-digit
organ growth previous
implications/read-across yet bake impact wuhan
coronaviru outbreak similar multi-industri compani
report earn far danah guidanc yet
incorpor impact coronaviru outbreak given on-going
busi disrupt china mix view
near-term downsid risk said note cepheid
busi engag privat public entiti
includ cdc design product detect viru
valuat high-end rel rang trade
premium peer adjust ep vs target rang
new price target assum trade premium vs
previous due upsid deal accret
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
best-in-class multi-industri name metric
hold much-covet posit among higher
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquir biopharma busi bil
announc acquir biopharma
busi bil impli reason deal multipl
ev/ebitda deal expect produc
mil cost save roughli
cash ep accret ge biopharma lead provid
instrument consum softwar support
research discoveri process develop manufactur
workflow biopharmaceut drug
given expens price-tag below-benchmark
expect return major integr stumbl ge
biopharma pall cepheid would damag faith
investor disciplin
bloomberg capit market estim upside/downside/target
given portfolio migrat toward higher-tech life scienc
busi believ re-rat toward
target rel price-to-earnings premium rang believ
trade high-end rang
due solid outlook investor enthusiasm
pend acquisit premium
target group multipl price-to-earnings
ep cash ep impli valuat support
sector perform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
believ stock may abl re-rat beyond high-
end rel rang premium
target group multipl adjust ep also see
potenti upsid ep cash ep reach
level includ acceler organ growth end
carri execut risk misstep
 integr could weigh stock addit
high-qual defens name would lag
market enter prolong risk-on environ favor
cyclic higher-beta stock could see price-to-earnings contract
premium peer midpoint
target rel rang also risk end
market slowdown result ep cash ep closer
valuat
takeaway result
revenu high growth
market high-
single-digit led china
india
us high-single-
digit western europ
mid-single-digit
cash ep consist posit pre-announce led
strength life scienc diagnost report adjust cash ep
consist compani posit pre-announce quarterli earn
would high-end guidanc rang see report
ep penni recently-rais estim partly-stal
consensu commun posit pre-announce organ revenu
growth stronger expect touch recently-rais estim
manag prior target led life scienc diagnost
environment appli solut adjust oper margin
expand bp y/i bp estim increment margin
impress overal oper line recently-rais estim
compris upsid life scienc diagnost environment appli
solut higher corpor expens below-the-lin item in-lin final
free cash flow convers quarter in-lin season averag
end year free cash flow convers robust
capit market compani report note organ revenu growth estim sector actual
issu cash ep guidanc exclud acquisit boost
deal accret estim issu initi cash ep guidanc
exclud accret acquisit expect
close consist manag tradit practic bake
impact uncomplet deal forecast said manag provid
color calibr impact deal net basi acquisit
expect accret significantli manag initi
estim assum deal close quarter-end would impli
accret impli cash ep guidanc includ would
touch consensu midpoint oper
forecast organ growth compris life scienc
diagnost environment appli solut total underli oper
margin expect expand y/i usual pace bp metric includ
corpor expens million per quarter incom million per quarter
tax rate rais cash ep estim
midpoint impli guidanc mostli due lower-than-expect financ cost
model assum deal close quarter-end
organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
exhibit danah earn guidanc vs estim consensu
revis accret assumpt
origin guidanc high-end initi guidanc rang
lower financ cost ad disclos abl take
advantag favor credit market condit especi europ rais financ
acquisit lower-than-expect interest rate specif
actual blend interest rate less origin estim
result estim annual interest cost million significantli
prior estim million equat increment cash ep
upsid vs origin framework
dilut life scienc divestitur deduct announc
sell sever small life scienc busi sartoriu ag roughli
million help obtain anti-trust regulatori approv ge biopharma acquisit
busi gener revenu million roughli life scienc
mix importantli emphas none divestitur come ge
biopharma portfolio note asset sale condit upon success
close acquisit detail pleas see report
yet incorpor materi impact wuhan coronaviru outbreak china
forecast similar multi-industri compani report earn far
danah guidanc yet incorpor impact wuhan coronaviru
outbreak intensifi past sever week given on-going disrupt
china viru includ longer-than-plan busi shutdown due extens
lunar new year holiday view signific downsid risk factor especi
china contribut total revenu said manag note
cepheid busi engag privat public entiti includ
cdc design product detect viru effort contain spread
initi cash ep guidanc rang bracket consensu
issu initi cash ep guidanc nice bracket consensu
time releas organ revenu growth expect roughli
prior forecast benefit bp top-lin tailwind
three extra sell day vs contrast three fewer sell day vs
remind guidanc includ potenti impact on-going wuhan
coronaviru outbreak china maintain cash ep estim
life scienc sale organ revenu compris mid-single-digit
beckman life scienc across major geographi product line low-single-digit
sciex tough y/i comp nearli growth pall double-digit thank
share gain newly-launch product thank adopt db growth tool
increas cadenc new product launch improv qualiti lower time-to-
market segment margin bp y/i quarter includ bp underli
expans look ahead life scienc expect achiev organ growth
diagnost organ revenu led double-digit radiomet leica
biosystem cepheid notabl cepheid cross billion annual revenu
decemb consist deliv annual organ revenu growth sinc
acquisit includ market share gain partli off-set low-single-digit growth
beckman diagnost due tough y/i comp segment margin bp y/i
quarter report underli basi look ahead diagnost expect
achiev organ growth
environment appli solut organ revenu
qualiti product id low-single-digit within product id videojet
low-single-digit led consum food beverag vertic esko x-rite
mid-single-digit within water qualiti hach low-single-digit due tough
y/i comp trojan due time larg project final chemtreat
mid-single-digit strength chemic food beverag vertic look ahead
environment appli solut expect achiev organ growth
upcom catalyst point monitor
track acquir billion announc
acquir ge life scienc biopharma busi cash purchas price
billion includ billion tax benefit net purchas price roughli billion
impli reason deal multipl price/sal ev/ebitda
surpris announc alway view natur buyer
busi given complementari natur portfolio ge biopharma
manag stand-alone oper compani within life scienc segment
rebrand cytiva expect credit rate downgrad still-
invest grade bbb follow deal addit busi expect produc
million annual cost save year-thre along potenti revenu synergi
though manag yet size opportun accret earn
increas estim cash ep contribut
prior estim deal expect close
ge biopharma leader bioprocess workflow expect grow organ
low-double-digit ge biopharma lead provid instrument
softwar consum support research process develop
manufactur discoveri workflow biopharmaceut drug deliv mid-
teen organ revenu growth roughli ebitda margin annual free
cash flow roughli billion look ahead manag expect ge biopharma
organ revenu growth deceler low-double-digit benefit
secular driver across biolog drug develop cell gene therapi demand
high growth market key product line within busi includ downstream
bioprocess revenu mix upstream bioprocess
detail ge
pleas see
report
announc ge
biopharma would
cytiva
divest small life scienc busi million help obtain regulatori approv
ge biopharma deal announc sell sever life
scienc busi sartoriu ag roughli million help obtain anti-trust regulatori
approv ge biopharma acquisit busi gener revenu
million life scienc mix includ label-fre biomolecular character
includ fortebio busi chromatographi hardwar resin includ pall process
chromatographi busi microcarri particl valid standard busi
note complet divestitur condit upon close ge
biopharma acquisit would character asset sale part routin anti-trust
concess disclos chosen result construct
discuss differ intern regulatori bodi manag estim
life scienc divestitur would dilut annual cash ep
believ could eventu pursu spin-out water qualiti follow
complet acquisit believ begin orchestr
separ best-in-class qualiti platform either stand-alone busi
pair product id billion revenu water qualiti portfolio compris
water analyt brand hach segment mix chemic disinfect brand chemtreat
ultraviolet disinfect brand trojan filtrat brand pall water
see water qualiti leagu within global water sector
recur revenu mix company-averag profit solid mid-single-digit organ
growth runway market share gain db implement commerci
execut new product innov busi sit squar high-end
water technolog continuum command higher valuat barrier entri margin
growth given scarciti invest water pure-play market today believ
publicli trade water qualiti would tremend appeal investor
rel price-to-earnings trade high-end rel rang share
current trade premium multi-industri sector report ep
cash ep believ stock trade premium target
group multipl high-end histor rel rang impli
price target support sector perform rate
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri peer group averag
share price trade premium weight averag price-to-earnings
publicly-trad peer report ep cash ep believ
deserv premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
compani report capit market estim
millionsmarjunsepdecmarjunsepdecmarjunsepdecmarjunsepdecseg revenueslif dentalenvironment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens incomerest dental discontinu exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper restat dental discontin oper electr equip multi-industri
given portfolio migrat toward higher-tech life scienc busi believ
re-rat higher toward target rel price-to-earnings premium rang
believ trade high-end rang due solid
outlook investor enthusiasm pend ge biopharma acquisit
premium target group multipl price-to-earnings adjust ep
cash ep impli valuat support sector perform rate
risk rate price target
acquisit one acquisit compani sector alway risk
overpay experienc integr difficulti major deal believ
integr stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
three segment life scienc diagnost environment appli solut
also oper differenti framework growth lean leadership tool process
known danah busi system across aspect oper includ product
develop qualiti control global sourc sale market
modestli headquart washington employ peopl global
